A new study claims that almost 60 per cent of clinical trial protocols for new drugs are amended during the trial, but one-third of those changes could have been avoided.

Researchers at the Tufts Centre for the Study of Drug Development found that completed protocols across all clinical generally incur 2.3 amendments, with each requiring an average of 6.9 changes to the protocol, leading to significant expense and delay.